Teva Pharma (TEVA) Tops Q4 EPS by 2c, provides guidance

Teva Pharma (NYSE: TEVA) reported Q4 EPS of $0.71, $0.02 better than the analyst estimate of $0.69. Revenue for the quarter came in at $4.23 billion versus the consensus estimate of $4.1 billion.

GUIDANCE:

Teva Pharma sees FY2025 EPS of $2.35-$2.65, versus the consensus of $2.78. Teva Pharma sees FY2025 revenue of $16.8-17.4 billion, versus the consensus of $17.087 billion.

For earnings history and earnings-related data on Teva Pharma (TEVA) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Alphabet (GOOGL) call put ratio 1.6 calls to 1 put with a focus on June 22 weekly calls as share price down 6%
• Trump: everybody is fully aware that Iran will agree to have major weapons inspections in order to ensure "nuclear honesty" long into future